EXECUTIVE INSIGHTS
DOMAIN EXPERTS
PLAYERS
PARTICIPANTS
-
MAR 2024
-
EDITION 18
-
TABLES 122
-
REGIONS 12
-
SEGMENTS 14
-
PAGES 196
-
US$ 5450
-
MCP-6736
-
JOIN OUR PANEL
EXECUTIVE ENGAGEMENTS BY TIER
-
CXO
-
VICE PRESIDENT
-
DIRECTOR
-
MANAGER
-
MARKETING
© Copy rights Global Industry Analysts, Inc., USA. www.strategyr.com All Rights Reserved.
OUR EXPERT PANELS
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
WHY PARTICIPATE?
Expertise to the Power of YOU!
- Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
- Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
- Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
- Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
- Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription
- The Economist
- MIT Technology Review
- Harvard Business Review
Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.
MARKETGLASS
BASIC
- Annual Prepaid Subscription
- Single-User
- 10,000 Data Room Credits/Month
- Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
- Use MarketGlassTM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
- My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
PREMIUM
- Annual Prepaid Subscription
- One Research Project With One Complimentary Update/Year
- 10-User License
- 10-User Peer-to-Peer Collaborative Features
- 200 Domain Expert Insights (With Name, Company, and Date)
- 50,000 Data Room Credits
- Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
- Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
- Use Your Own Data and MarketGlassTM Data Room Content.
- My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
- Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges
ENTERPRISE
- Annual Prepaid Subscription
- Four Research Projects With One Complimentary Update/Year
- 25-User License
- 25-User Peer-to-Peer Collaborative Engagements
- 500 Domain Expert Insights (With Name, Company, and Date)
- 150,000 Data Room Credits
- Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
- Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
- Use Your Own Data and MarketGlassTM Data Room Content.
- My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
- Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges
HIGHLIGHTS & REPORT INDEX
Global Companion Diagnostics Market to Reach $13.8 Billion by 2030
The global market for Companion Diagnostics estimated at US$11.9 Billion in the year 2023, is expected to reach US$13.8 Billion by 2030, growing at a CAGR of 1.8% over the period 2023-2030. Assay kits & Reagents, one of the segments analyzed in the report, is expected to record 1.2% CAGR and reach US$8.7 Billion by the end of the analysis period. Growth in the Software & Services segment is estimated at 3% CAGR for the next 8-year period.
The U.S. Market is Estimated at $3.6 Billion, While China is Forecast to Grow at 1.3% CAGR
The Companion Diagnostics market in the U.S. is estimated at US$3.6 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 1.3% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 0.9% and 0.4% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately -0.8% CAGR.
Introducing Our Exciting New Report Features for 2024
» Full access to influencer engagement stats
» Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants` privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.
» Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities
» Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas
» Complimentary report updates for one year
» Competitor coverage with global market shares of major players
» Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies
» Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes
What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.
SELECT PLAYERS
Abbott Molecular; Agilent Technologies, Inc.; bioMérieux SA; Cepheid; Danaher Corporation; F. Hoffmann-La Roche Ltd.; Foundation Medicine Inc.; Laboratory Corporation of America® Holdings; Leica Biosystems Nussloch GmbH; Merck & Co. Inc.; Myriad Genetics Inc.; NeoGenomics Laboratories, Inc.; QIAGEN N.V.; Quest Diagnostics Inc.; Thermo Fischer Scientific Inc.
SEGMENTS
» Product & Service (Assay kits & Reagents, Software & Services) » Technology (Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS), Other Technologies) » Indication (Oncology, Neurology, Other Indications) » End-Use (Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs, Other End-Uses)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Global Economic Update |
Companion Diagnostics: An Introductory Prelude |
Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development |
Broader Scope and Applications Rev Up Growth Opportunities |
Healthy Growth Projected over the Next Few Years |
Developed Regions: Key Revenue Contributors |
Market Witnesses Fast Paced Growth in Developing Regions |
Northbound Trajectory in R&D Spending Creates Conducive Environment |
Prevailing Economic Scenario Favors Funding Pattern |
Companion Diagnostics – Global Key Competitors Percentage Market Share in 2022 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
Growing Significance of Personalized Medicine Remains a Major Market Driver |
Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum |
Herceptin Lays the Road for Companion Diagnostics |
Oncology - Dominant Therapy Area for CDx |
Rising Incidence of Cancer Propels the Need for CDx Tests |
Technology Advancements to Widen CDx Use Case |
PCR: Dominant Technology Type for CDx Testing |
Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing |
Significant Role of Biomarkers in Companion Diagnostics |
Critical Healthcare Needs of Aging Population Underpin CDx Sales |
Regulatory Scenario Favors CDx Market |
Resolving Prevailing Challenges: Critical for Future Growth of CDx Market |
4. GLOBAL MARKET PERSPECTIVE |
World Recent Past, Current & Future Analysis for Companion Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Assay kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Assay kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Polymerase Chain Reaction (PCR) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Polymerase Chain Reaction (PCR) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Immunohistochemistry (IHC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Immunohistochemistry (IHC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for In Situ Hybridization (ISH) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Next-Generation Sequencing (NGS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Next-Generation Sequencing (NGS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Pharmaceutical & Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Pharmaceutical & Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Reference Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for CROs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Companion Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030 |
III. MARKET ANALYSIS |
UNITED STATES |
Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E) |
USA Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
USA 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030 |
USA Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
USA 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030 |
USA Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
USA 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030 |
USA Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
USA 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030 |
CANADA |
Canada Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Canada 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030 |
Canada Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Canada 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030 |
Canada Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Canada 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030 |
Canada Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Canada 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030 |
JAPAN |
Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E) |
Japan Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Japan 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030 |
Japan Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Japan 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030 |
Japan Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Japan 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030 |
Japan Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Japan 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030 |
CHINA |
Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E) |
China Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
China 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030 |
China Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
China 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030 |
China Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
China 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030 |
China Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
China 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030 |
EUROPE |
Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E) |
Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
Europe 8-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Europe 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Europe 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Europe 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Europe 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030 |
FRANCE |
Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E) |
France Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
France 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030 |
France Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
France 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030 |
France Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
France 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030 |
France Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
France 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030 |
GERMANY |
Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E) |
Germany Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Germany 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030 |
Germany Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Germany 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030 |
Germany Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Germany 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030 |
Germany Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Germany 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030 |
ITALY |
Italy Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Italy 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030 |
Italy Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Italy 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030 |
Italy Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Italy 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030 |
Italy Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Italy 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030 |
UNITED KINGDOM |
Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E) |
UK Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
UK 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030 |
UK Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
UK 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030 |
UK Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
UK 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030 |
UK Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
UK 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of Europe 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of Europe 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of Europe 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of Europe 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030 |
ASIA-PACIFIC |
Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Asia-Pacific 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Asia-Pacific 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Asia-Pacific 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Asia-Pacific 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030 |
REST OF WORLD |
Rest of World Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of World 8-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2023 & 2030 |
Rest of World Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of World 8-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2023 & 2030 |
Rest of World Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of World 8-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2023 & 2030 |
Rest of World Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of World 8-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2023 & 2030 |
IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com
DIFFERENTIATORS
Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .
What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).
WHAT SETS US APART
FULL STACK DATA ACCESS
- Primary Research Cluster Data
- Influencer Engagement Stats
- Evidence of Primary Research
- List of Companies Engaged
- Hundreds of Pages of Research
- Peer Collaborative Interactions
- Enterprise Data Exchanges
- MarketGlassTM Platform Insider
- Geographic Pricing Dynamics
- Competitive Shares by Country
- Brand Curation & Insights
- Domain Expert Pool
Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.
Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.
Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.
Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.
Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.
Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.
Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.